Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 1, 2013, Pages 59-70

  Tanigawa, Takahiko ^a   Kaneko, Masato ^a   Hashizume, Kensei ^a   Kajikawa, Mariko ^a   Ueda, Hitoshi ^a   Tajiri, Masahiro ^a   Paolini, John F ^b   Mueck, Wolfgang ^c  

^a BAYER YAKUHIN LTD   (Japan)

^b BAYER CORPORATION   (United States)

^c BAYER PHARMA AG   (Germany)

Author keywords

Anticoagulants; Atrial fibrillation; Factor xa; Japan; Pharmacokinetics; Rivaroxaban; Stroke

Indexed keywords

ALANINE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 10A; NEOPLASTIN PLUS; RIVAROXABAN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CARDIOVERSION; CAUCASIAN; CEREBROVASCULAR ACCIDENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; HEART ATRIUM FIBRILLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPANESE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PROTHROMBIN TIME;

EID: 84874615039     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-034     Document Type: Article

References (45)

1. Ohsawa, M., Okayama, A., Sakata, K., Kato, K., Itai, K., Onoda, T. and Ueshima, H.: Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J. Epidemiol., 15: 194-196 (2005).
2. Tanizaki, Y., Kiyohara, Y., Kato, I., Iwamoto, H., Nakayama, K., Shinohara, N., Arima, H., Tanaka, K., Ibayashi, S. and Fujishima, M.: Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke, 31: 2616-2622 (2000).
3. Stroke Risk in Atrial Fibrillation Working Group: Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology, 69: 546-554 (2007).
4. Lutz, W., Sanderson, W. and Scherbov, S.: The coming acceleration of global population ageing. Nature, 451: 716-719 (2008).
5. World Health Organization: World Population Ageing 1950-2050; Chapter IV. Demographic Profile of the Older Population. http://www.un.org/esa/population/publications/worldageing19502050/pdf/90chapteriv.pdf (updated 2009; last accessed 10 January 2011).
6. Turin, T. C., Kokubo, Y., Murakami, Y., Higashiyama, A., Rumana, N., Watanabe, M. and Okamura, T.: Lifetime risk of stroke in Japan. Stroke, 41: 1552-1554 (2010).
7. Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. and Manning, W. J.: American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest, 133: 546S-92S (2008).
8. Hart, R. G., Pearce, L. A. and Aguilar, M. I.: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med., 146: 857-867 (2007).
9. Camm, A. J., Kirchhof, P., Lip, G. Y., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., Al Attar, N., Hindricks, G., Prendergast, B., Heidbuchel, H., Alfieri, O., Angelini, A., Atar, D., Colonna, P., De Caterina, R., De Sutter, J., Goette, A., Gorenek, B., Heldal, M., Hohloser, S. H., Kolh, P., Le Heuzey, J. Y., Ponikowski, P., Rutten, F. H., Vahanian, A., Auricchio, A., Bax, J., Ceconi, C., Dean, V., Filippatos, G., Funck-Brentano, C., Hobbs, R., Kearney, P., McDonagh, T., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Vardas, P. E., Widimsky, P., Vardas, P. E., Agladze, V., Aliot, E., Balabanski, T., Blomstrom-Lundqvist, C., Capucci, A., Crijns, H., Dahlof, B., Folliguet, T., Glikson, M., Goethals, M., Gulba, D. C., Ho, S. Y., Klautz, R. J., Kose, S., McMurray, J., Perrone, F. P., Raatikainen, P., Salvador, M. J., Schalij, M. J., Shpektor, A., Sousa, J., Stepinska, J., Uuetoa, H., Zamorano, J. L. and Zupan, I.: Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J., 31: 2369-2429 (2010)
10. Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J. Y., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L. and Wann, L S.: 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 123: e269-e367 (2011).
11. Japanese Circulation Society Joint Working Group: Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ. J., 74: 2479-2500 (2010).
12. Yasaka, M. and Yamaguchi, T.: Secondary prevention of stroke in patients with nonvalvular atrial fibrillation: optimal intensity of anticoagulation. CNS Drugs, 15: 623-631 (2001).
13. Yasaka, M., Minematsu, K. and Yamaguchi, T.: Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern. Med., 40: 1183-1188 (2001).
14. Atarashi, H., Inoue, H., Okumura, K., Yamashita, T., Kumagai, N. and Origasa, H.: Present status of anticoagulation treatment in Japanese patients with atrial fibrillation. Circ. J., 75: 1328-1333 (2011).
15. Hylek, E. M.: The need for new oral anticoagulants in clinical practice. J. Cardiovasc. Med. (Hagerstown), 10: 605-609 (2009).
16. Nieuwlaat, R., Capucci, A., Camm, A. J., Olsson, S. B., Andresen, D., Davies, D. W., Cobbe, S., Breithardt, G., Le Heuzey, J. Y., Prins, M. H., Lévy, S. and Crijns, H. J.: European Heart Survey Investigators: Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur. Heart J., 26: 2422-2434 (2005).
17. Waldo, A. L., Becker, R. C., Tapson, V. F. and Colgan, K. J.: NABOR Steering Committee: Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J. Am. Coll. Cardiol., 46: 1729-1736 (2005).
18. Ruff, C. T., Giugliano, R. P., Antman, E. M., Crugnale, S. E., Bocanegra, T., Mercuri, M., Hanyok, J., Patel, I., Shi, M., Salazar, D., McCabe, C. H. and Braunwald, E.: Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J., 160: 635-641 (2010).
19. Lopes, R. D., Alexander, J. H., Al-Khatib, S. M., Ansell, J., Diaz, R., Easton, J. D., Gersh, B. J., Granger, C. B., Hanna, M., Horowitz, J., Hylek, E. M., McMurray, J. J., Verheugt, F. W. and Wallentin, L.: ARISTOTLE Investigators: Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am. Heart J., 159: 331-339 (2010).
20. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B. S., Darius, H., Diener, H. C., Joyner, C. D. and Wallentin, L.: RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 361: 1139-1151 (2009).
21. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A. and Wallentin, L.: Newly identified events in the RE-LY trial. N. Engl. J. Med., 363: 1875-1876 (2010).
22. Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H. C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., Talajic, M., Zhu, J., Pais, P., Budaj, A., Parkhomenko, A., Jansky, P., Commerford, P., Tan, R. S., Sim, K. H., Lewis, B. S., Van Mieghem, W., Lip, G. Y. H., Kim, J. H., Lanas-Zanetti, F., Gonzalez-Hermosillo, A., Dans, A. L., Munawar, M., O'Donnell, M., Lawrence, J., Lewis, G., Afzal, R. and Yusuf, S.: AVERROES Steering Committee and Invetigators: Apixaban in patients with atrial fibrillation. N. Engl. J. Med., 364: 806-817 (2011).
23. Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., Becker, R. C., Nessel, C. C., Paolini, J. F., Berkowitz, S. D., Fox, K. A. A. and Califf, R. M.: ROCKET AF Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med., 365: 883-891 (2011).
24. Weinz, C., Schwarz, T., Kubitza, D., Mueck, W. and Lang, D.: Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab. Dispos., 37: 1056-1064 (2009).
25. Mueck, W., Becka, M., Kubitza, D., Voith, B. and Zuehlsdorf, M.: Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in healthy subjects. Int. J. Clin. Pharmacol. Ther., 45: 335-344 (2007).
26. Kubitza, D., Becka, M., Wensing, G., Voith, B. and Zuehlsdorf, M.: Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol., 61: 873-880 (2005).
27. Mueck, W., Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Kälebo, P., Muelhofer, E., Misselwitz, F. and Eriksson, B. I.: Population pharmacokinetics and pharmacodynamics of once and twicedaily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb. Haemost., 100: 453-461 (2008).
28. Mueck, W., Eriksson, B. I., Bauer, K. A., Borris, L., Dahl, O. E., Fisher, W. D., Gent, M., Haas, S., Huisman, M. V., Kakkar, A. K., Kälebo, P., Kwong, L. M., Misselwitz, F. and Turpie, A. G. G.: Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct Factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin. Pharmacokinet., 47: 203-216 (2008).
29. Agnelli, G., Gallus, A., Goldhaber, S. Z., Haas, S., Huisman, M. V., Hull, R. D., Kakkar, A. K., Misselwitz, F. and Schellong, S.: ODIXa-DVT Study Investigators: Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation, 116: 180-187 (2007).
30. Büller, H. R., Lensing, A. W., Prins, M. H., Agnelli, G., Cohen, A., Gallus, A. S., Misselwitz, F., Raskob, G., Schellong, S. and Segers, A.: Einstein-DVT Dose-Ranging Study investigators: A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN-DVT Dose-Ranging Study. Blood, 112: 2242-2247 (2008).
31. World Health Organization: Global database on body mass index. http://apps.who.int/bmi/index.jsp (updated 2010; last accessed 10 January 2011).
32. Johansson, L. C., Andersson, M., Fager, G., Gustafsson, D. and Eriksson, U. G.: No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin. Pharmacokinet., 42: 475-484 (2003).
33. Wernevik, L. C., Nystrom, P., Andersson, M., Johnsson, G., Bylock, A., Nakanishi, T. and Eriksson, U. G.: Comparable pharmacokinetics and pharmacodynamics of melagatran in Japanese and Caucasian volunteers after oral administration of the direct thrombin inhibitor ximelagatran. Clin. Pharmacokinet., 45: 85-94 (2006).
34. Mueck, W., Lensing, A. W., Agnelli, G., Decousus, H., Prandoni, P. and Misselwitz, F.: Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin. Pharmacokinet., 50: 675-686 (2011).
35. Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W. and Radford, M. J.: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA, 285: 2864-2870 (2001).
36. Rohde, G.: Determination of rivaroxaban-a novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatographytandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 872: 43-50 (2008).
37. Kubitza, D., Becka, M., Voith, B., Zuehlsdorf, M. and Wensing, G.: Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin. Pharmacol. Ther., 78: 412-421 (2005).
38. Tomita, F., Kohya, T., Sakurai, M., Kaji, T., Yokoshiki, H., Sato, M., Sasaki, K., Itoh, Y., Konno, M. and Kitabatake, A.: Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan. Jpn. Circ. J., 64: 653-658 (2000).
39. Halperin, J. L.: Executive Steering Committee SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am. Heart J., 146: 431-438 (2003).
40. Olsson, S. B.: Executive Steering Committee of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet, 362: 1691-1698 (2003).
41. Jones, C. A., McQuillan, G. M., Kusek, J. W., Eberhardt, M. S., Herman, W. H., Coresh, J., Salive, M., Jones, C. P. and Agodoa, L. Y.: Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am. J. Kidney Dis., 32: 992-999 (1998).
42. Kubitza, D., Becka, M., Roth, A. and Mueck, W.: Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr. Med. Res. Opin., 24: 2757-2765 (2008).
43. Kubitza, D., Becka, M., Zuehlsdorf, M. and Mueck, W.: Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J. Clin. Pharmacol., 47: 218-226 (2007).
44. Kubitza, D., Becka, M., Mueck, W., Halabi, A., Maatouk, H., Klause, N., Lufft, V., Wand, D. D., Philipp, T. and Bruck, H.: Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban-an oral, direct Factor Xa inhibitor. Br. J. Clin. Pharmacol., 70: 703-712 (2010).
45. Zhao, X., Sun, P., Zhou, Y., Liu, Y., Zhang, H., Mueck, W., Kubitza, D., Bauer, R. J., Zhang, H. and Cui, Y.: Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br. J. Clin. Pharmacol., 68(1): 77-88 (2009).